← All trials
NCT02165202
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2014
- Primary completion
- Oct 1, 2017
- Completion date
- Oct 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 132
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- PATHLead sponsor
- Rutgers UniversityOverall official - principal investigator
- Bronx Lebanon Hospital CenterOverall official - principal investigator
- University of ZimbabweOverall official - principal investigator
- Desmond Tutu HIV CentreStudy chair
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Bill and Melinda Gates FoundationCollaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.